Status:
COMPLETED
Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia
Lead Sponsor:
Sheba Medical Center
Conditions:
Ataxia
Chorea
Eligibility:
All Genders
4-50 years
Phase:
PHASE4
Brief Summary
Ataxia-Telangiectasia A-T is a neurodegenerative disorder of the cerebellum, manifesting with ataxia, as well as extrapyramidal features. Treatment of A-T is discouraging, since no treatment seems to ...
Detailed Description
Ataxia-Telangiectasia (A-T) is a complex multisystem disorder with neurodegenerative course, immune deficiency, and tendency to develop malignancies .The clinical picture includes progressive cerebell...
Eligibility Criteria
Inclusion
- diagnosis of A-T
- significant functional disability
- age over 4 years
Exclusion
- major comorbidity: active malignancy requiring chemotherapy, kidney or liver failure
- sexually active
- known hypersensitivity to amantadine
- previous treatment with amantadine in the 2 months preceding the study
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00950196
Start Date
November 1 2008
End Date
November 1 2009
Last Update
June 28 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel